Danaher Co. (NYSE:DHR) is experiencing significant fluctuations in its shareholdings. Major financial institutions, including Stock Yards Bank & Trust Co, Tritonpoint Wealth LLC, and Wedmont Private Capital among others, have divested from the company. Simultaneously, entities like Manitou Investment Management Ltd, Baker Chad R, and Azzad Asset Management Inc, have increased their stakes. Coverage from CNBC's Jim Cramer states Danaher's China core revenue experienced a high single-digit percentage drop in Q3. The company launched partnership with AstraZeneca for diagnostic tests in precision medicine, a strategic move that might boost Danaher's standing in the booming precision medicine market. However, accelerated sell-offs by big investors cause investor caution. Financial pundits encourage near-term avoidance of the stock due to risk factors. Yet others believe Danaher has prospects for significant long-term growth and point out that the recent dip in shares offers a solid entry point for potential investors.
Danaher Corporation DHR News Analytics from Mon, 23 Dec 2024 08:00:00 GMT to Sat, 14 Jun 2025 11:33:47 GMT -
Rating 0
- Innovation -2
- Information 6
- Rumor -5
